Mandate

Vinge has advised Apotea in connection with its listing on Nasdaq Stockholm

Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on November 26, 2024 and the first day of trading is December 6, 2024.

The offering price was SEK 58 per ordinary share, corresponding to a total market value for all ordinary shares in Apotea of approximately SEK 6 billion. The total value of the offering amounts to approximately SEK 1,880 million, provided that the overallotment option is exercised in full.

Apotea is Sweden’s leading online pharmacy by market share with the goal of becoming the largest pharmacy in Sweden and hence also in the Nordics. With the widest assortment on the market, low prices and quick deliveries, the company facilitates everyday life for its three million active customers.

Vinge’s team primarily consisted of Jesper Schönbeck, Amanda Knutsson, Anna Svensson, Lorin Arabi, Karin Karsten and Elias Kröger (Capital Markets and Public M&A), Victor Ericsson, Emelie Svanberg, Ellenor Eckerborn och Marcus Svärd (Corporate Tax), Sam Seddigh and Emil Lindwall (Employment), Helena Rosén Andersson and Hilda Ivarsson (Permits), Fredrika Hjelmberg, Mario Saad and Siri Blomberg (Commercial agreements, IT and GDPR), Ian Jonson (Intellectual Property) and Sofia Haggren (Financing).

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025